Data gathered: November 23
AI Stock Analysis - Recursion Pharmaceuticals (RXRX)
Analysis generated September 9, 2024. Powered by Chat GPT.
Recursion Pharmaceuticals is a biotechnology company focused on accelerating drug discovery through the integration of biology, chemistry, automation, and sophisticated data analytics. By leveraging their proprietary platform that combines experimental biology and bioinformatics, Recursion Pharmaceuticals aims to rapidly identify and develop novel therapeutics for various disease areas.
Stock Alerts - Recursion Pharmaceuticals (RXRX)
 |
Recursion Pharmaceuticals | November 21 Price is down by -5.6% in the last 24h. |
|
Recursion Pharmaceuticals | November 20 Price is down by -5.1% in the last 24h. |
|
Recursion Pharmaceuticals | November 16 Insider Alert: Gibson Christopher is selling shares |
|
Recursion Pharmaceuticals | November 15 Price is down by -5.5% in the last 24h. |
Alternative Data for Recursion Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 32 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 28,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 32 | Sign up | Sign up | Sign up |
| Patents | 35 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 26 | Sign up | Sign up | Sign up |
| Facebook Followers | 658 | Sign up | Sign up | Sign up |
| Reddit Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 56 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,958 | Sign up | Sign up | Sign up |
| Twitter Followers | 12,426 | Sign up | Sign up | Sign up |
| Twitter Mentions | 21 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 2,770 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 70 | Sign up | Sign up | Sign up |
| Linkedin Employees | N/A | Sign up | Sign up | Sign up |
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
| Price | $5.70 |
| Target Price | Sign up |
| Volume | 13,660,000 |
| Market Cap | $2.24B |
| Year Range | $5.7 - $11.42 |
| Dividend Yield | 0% |
| Analyst Rating | 29% buy |
| Industry | Biotechnology |
In the news
 |
Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)November 21 - ETF Daily News |
|
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.9% on Insider SellingNovember 16 - ETF Daily News |
 |
Recursion Pharmaceuticals director Blake Borgeson sells $87,457 in stockNovember 14 - Investing.com |
 |
Recursion Pharmaceuticals CFO Michael Secora sells $229,504 in stockNovember 14 - Investing.com |
Recursion Pharmaceuticals : Proxy Results Form 8 KNovember 13 - Finnhub |
|
Recursion Pharmaceuticals : and Exscientia Shareholders Approve the Proposed Combination Form 8 KNovember 12 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 26M | 55M | -29M | -96M | -93M | -0.340 |
| Q2 '24 | 14M | 46M | -32M | -98M | -96M | -0.400 |
| Q1 '24 | 14M | 46M | -32M | -91M | -89M | -0.390 |
| Q4 '23 | 11M | 45M | -34M | -93M | -94M | -0.420 |
| Q3 '23 | 11M | 43M | -33M | -93M | -90M | -0.430 |
Insider Transactions View All
| Gibson Christopher filed to sell 762,656 shares at $7.4. November 15 '24 |
| Secora Michael filed to sell 1,499,631 shares at $7.7. November 14 '24 |
| Borgeson Blake filed to sell 7,066,113 shares at $7.6. November 14 '24 |
| Marriott Tina filed to sell 521,138 shares at $6.3. October 28 '24 |
| Borgeson Blake filed to sell 7,089,007 shares at $6.7. October 17 '24 |
Similar companies
Read more about Recursion Pharmaceuticals (RXRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Recursion Pharmaceuticals?
The Market Cap of Recursion Pharmaceuticals is $2.24B.
What is the current stock price of Recursion Pharmaceuticals?
Currently, the price of one share of Recursion Pharmaceuticals stock is $5.70.
How can I analyze the RXRX stock price chart for investment decisions?
The RXRX stock price chart above provides a comprehensive visual representation of Recursion Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Recursion Pharmaceuticals shares. Our platform offers an up-to-date RXRX stock price chart, along with technical data analysis and alternative data insights.
Does RXRX offer dividends to its shareholders?
As of our latest update, Recursion Pharmaceuticals (RXRX) does not offer dividends to its shareholders. Investors interested in Recursion Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Recursion Pharmaceuticals?
Some of the similar stocks of Recursion Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.